ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three ...

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...

One specific hit, called S656 acts as a molecular glue degrader (MGD), that mediates the CRL4-dependent proteolysis of cyclin K. Structurally, S656 features a moiety that binds to the ATP binding site ...

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), Monday announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial evaluating azenosertib in Cyclin E1+ platinum ...

We are grateful to our patients and their families for participating in this trial, which has the potential to result in a treatment option for thousands of women diagnosed with Cyclin E1+ PROC.” ...

I’m a longtime lover of pen and paper, so E Ink tablets have been intriguing to me ever since they started becoming more widely available. After having hundreds of half-filled notebooks over the ...

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.

Presentation Details Title: Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated ... Poster Section 52 Poster Board Number: 19 Catherine E. Gleason, Ranya Odeh, Frances Hamkins-Indik ...

Key molecular alterations in ovarian cancer include Cyclin E1 overexpression and TP53 mutations, both of which disrupt cell cycle regulation and contribute to poor prognosis. Cyclin E1 overexpression ...

Cyclin E1 (CCNE1) expression has been associated with replicative stress and defects in double-strand break repair in multiple tumor types; however, this has yet to be demonstrated in ovarian cancer.

Get Instant Summarized Text (Gist) Cyclin-dependent kinase inhibitor 1A (CDKN1A) is consistently upregulated in metabolic dysfunction-associated steatotic liver disease (MASLD) and correlates with ...